Argonaute 2 drives resistance to immune checkpoint inhibitors in immunorefractory non-small cell lung cancer
Dario P. Anobile, Layla Barbar, Emile Maucotel, Alexis Cornec et autres
One of the first-line treatments for advanced non-small cell lung cancer (NSCLC) are immune checkpoint inhibitors (ICI), which activate the antitumor immune response. Despite their success, ICI remain ineffective in many patients, highlighting the need for strategies to overcome resistance. Most efforts …
fr (code pays fourni par la source)
0 citations
PLoS Biology